Form 4: Immunome Inc. Insider Trades: CMO Sells Shares

Immunome Inc. Chief Medical Officer Robert Lechleider reported transactions involving the sale of company stock, executed under a pre-arranged trading plan.

Summary

• Robert Lechleider, Chief Medical Officer of Immunome Inc., reported a series of transactions on June 25, 2026.
• These transactions included the acquisition of 55,000 shares of common stock at $8.73 per share.
• Additionally, Lechleider disposed of 40,580 shares at a weighted average price of $19.56 and 14,420 shares at a weighted average price of $20.66.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on March 26, 2026.
• Following these transactions, Lechleider beneficially owns 30,225 shares directly and 15,805 shares directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a key executive, despite the use of a Rule 10b5-1 plan.

Positives

• The acquisition of 55,000 shares at $8.73 per share suggests continued investment or compensation related to employee stock options.
• The execution of sales under a Rule 10b5-1 plan indicates a structured and pre-planned approach to stock disposition, which can mitigate insider trading concerns.

Negatives

• The disposal of a significant number of shares (55,000 shares in total) by a key executive could be interpreted negatively by the market.
• The sales occurred at prices significantly higher than the acquisition price, indicating a profitable exit for the reporting person.

Risks

• Potential for negative market perception due to a key executive selling a substantial number of shares.
• The specific prices of sales ($19.27 to $20.255 and $20.275 to $21.02) indicate a significant value realized by the reporting person.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily reports past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
• Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the Issuer, or any security holder of the Issuer.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by Immunome Inc.'s Chief Medical Officer is a common practice to manage stock sales in a way that avoids accusations of insider trading, especially in the biotechnology sector where stock prices can be volatile.

Stakeholder Impact

• Shareholders may view the sale of shares by a key executive with caution, potentially impacting short-term stock sentiment.
• Employees may interpret the sale as a sign of confidence or lack thereof from management, depending on other company news.
• Creditors and suppliers are unlikely to be directly impacted by this insider transaction.

Next Steps

• Continued monitoring of insider trading activity for Immunome Inc.
• Analysis of future Form 4 filings to observe any further transactions by management.

Key Dates

Recommendation

The filing reports insider stock sales executed under a pre-planned Rule 10b5-1 trading plan. While insider selling can be a negative signal, the structured nature of the plan mitigates concerns about trading on non-public information. Without additional context on the company's performance or future prospects, a 'hold' recommendation is appropriate, suggesting investors await further developments or financial reports.

Keywords

Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Immunome Inc., IMNM, Chief Medical Officer, Beneficial Ownership, Stock Option